Funding
Funding not disclosed
Founders
Product
Problem
Current medical diagnostic testing often involves lengthy turnaround times and requires specialized laboratory infrastructure, delaying critical treatment decisions. This can lead to suboptimal patient outcomes, particularly for time-sensitive conditions requiring rapid molecular identification.
Solution
Velocity DX offers a point-of-care diagnostic platform designed for rapid nucleic acid detection. Our proprietary assay technology enables accurate and timely results directly at the patient's bedside or in decentralized clinical settings. This approach streamlines the diagnostic workflow, facilitating quicker clinical interventions and improved patient management. By reducing reliance on centralized laboratories, Velocity DX enhances accessibility to essential diagnostic information.
Target Audience
Our primary customers are healthcare providers, including clinics, hospitals, and diagnostic laboratories, seeking to expedite patient diagnosis and treatment initiation.
Features
- Novel nucleic acid detection chemistry for rapid and sensitive molecular diagnostics.
- Point-of-care platform designed for decentralized testing environments.
- Integrated sample-to-result workflow to minimize manual steps.
- High-throughput capability for processing multiple samples concurrently.
- User-friendly interface requiring minimal specialized training.